Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Li Watsek reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.
Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.1...
This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. This is ...
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target from $35...
Cantor Fitzgerald analyst Alethia Young reiterates Arcus Biosciences (NYSE:RCUS) with a Overweight.
Truist Securities analyst Asthika Goonewardene maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price targe...
